L’immunothérapie de première ligne pour les CBNPC de stades avancés (sans addiction oncogénique)

Ettinger, 2018, NCCN Guidelines Insights: NonSmall Cell Lung Cancer, Version 5.2018, J Natl Compr Canc Netw, 16, 807, 10.6004/jnccn.2018.0062 Reck, 2016, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Lopes, 2018, Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) > 1%: Open-label, phase 3 KEYNOTE-042 study, J Clin Oncol, 36, 10.1200/JCO.2018.36.18_suppl.LBA4 Gandhi, 2018, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005 Paz-Ares, 2018, Phase 3 study of carboplatin-paclitaxel/nabpaclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC), J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.105 Jotte, 2018, IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. abstr. LBA9000, actualize. IMpower 131, J Clin Oncol, 36, 10.1200/JCO.2018.36.18_suppl.LBA9000 Hellmann, 2018, Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946 Borghaei, 2018, Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.9001 Socinski, 2018, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948 Socinski, 2018, Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.9002 Goldberg, 2018, Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.2009